Kornimate/medical-research-clean huggingface dataset:
observational study in utero - placental 3d doppler examination: interest for pre-eclampsia screening during pregnancy

Conditions: Pre-eclampsia; Intra-uterine Growth Restriction; Placental Insufficiency; 3D Doppler Ultrasound

Summary: pre-eclampsia and intra uterine growth restriction (iugr) represent major complications for pregnant women, with a high related maternal and fetal morbidity and mortality. it is now widely admitted that these pathologies, which can concern up to 7% of pregnancies, are in relation with hypo-perfusion of the placenta because of an early deficient trophoblast invasion and uterine vascular remodelling.advances in ultrasound imaging now permit non invasive 3d volume and doppler signal quantification using automatic acquisitions.quantitative comparison of volumes and doppler parameters between control pregnancies and iugr ought to confirm the theory of utero-placental hypo-perfusion. this technique might allow an earlier prediction for iugr. the aim of this study is to evaluate the interest of 3d doppler quantification as a new screening tool for pre eclampsia and iugr.

one hundred high risk women and 70 low risk women will be included. inclusion criteria for the high risk group are: personal history of pre eclampsia and/or iugr in a previous pregnancy, diabetes, auto-immune syndrome such as lupus, hypertension, renal insufficiency, and anti-phospholipid syndrome.patients (over 18 years old) will be included between 11 and 14(+6days) wg. only singletons pregnancies will be included.3d doppler standardized acquisitions of the utero-placental unit will be performed at each usual ultrasound examination of the pregnancy.data will be analysed after delivery, in terms of quantified doppler values, comparing two groups: pregnancies with pre eclampsia / iugr (group with pathology) and normal pregnancies (control group).this is an observational study.

Eligibility criteria:
inclusion criteria: * age eligible for study up to 18 years * gestational age between 11 to 14 weeks for the first visit (first-trimester pregnancy).-singleton pregnancy * consent to participate in the study * patients affiliated to social security group 1: -personal history of: * preeclampsia during a previous pregnancy: blood pressure more than 140 mmhg systolic and/or 90 mmhg diastolic + proteinuria * diabetes * iugr during a previous pregnancy (birth weight \< 10th centile) * hypertension * renal insufficiency * autoimmune disease : antiphospholipid syndrome group 2:absence of all the group 1 affiliation criteria. exclusion criteria: * participating in the study * unability to understand the study * set back of patient consent.

Keywords: pre-eclampsia utero-placental unit vascularization hypertension, pregnancy- induced iugr screening 3d doppler ultrasound
observational study in type 2 diabetics failing on oral antidiabetic therapy and starting on insulin treatment

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this study is conducted in europe. the aim of this observational study is to evaluate glycaemic control in subjects with type 2 diabetes using once daily levemir® as initiation of insulin therapy in hungary.


Eligibility criteria:
inclusion criteria: * patient with type 2 diabetes inadequately controlled by oad therapy based on the discretion of individual physician * patient willing to sign informed consent * particular attention should be paid to age limits, indications and contraindications and the drug interactions that are listed within the product labels exclusion criteria: * subjects with diagnosed type 1 diabetes mellitus * subjects who are unlikely to comply with observational plan, (e.g., uncooperative attitude, inability to return for further visits) * subjects with hypersensitivity to levemir® or to any of the ingredients * women of childbearing potential, who are pregnant, breast-feeding or intend to become pregnant within next 12 months.
combine serratus anterior plane block versus erector spinae plane block in coronary bypass surgery

Conditions: Cardiac Surgery; Postoperative Pain; Regional Anesthesia Morbidity

Summary: even though erector spinae plane (esp) block is shown to be efficient in cardiac surgery, the combine serratus anterior plane (csap) block is still controversial if it has an efficient analgesic effect for sternotomy and drain tube pain relief. this study aims to compare esp block and csap block for postoperative analgesia in coronary bypass surgery patients.

acute postoperative pain after cardiac surgery originates various surgical procedures that may cause pain including the incision of tissues, sternotomy, the separation of bone-joint structures, the severity and duration of these applications, the use of chest tubes, and the patient's personal inflammatory may affect the response to these stimuli. postoperative pain is a critical risk factor for the development of pulmonary and cardiovascular complications such as atelectasis, cardiac ischemia, and arrhythmias. researchers claim that adding techniques to iv drugs, such as thoracic epidural anesthesia, paravertebral block, or erector spinae plane block (esp) to multimodal analgesia regimens positively affect recovery. although the efficacy of esp block in providing postoperative analgesia has been demonstrated in many studies, there is no study comparing csap and esp block in cardiac surgery.

Eligibility criteria:
inclusion criteria: * adult patients who will undergo coronary artery bypass grafting surgery with median sternotomy exclusion criteria: * emergency surgeries * patients with allergic reactions to anesthesia and analgesia drugs to be used * patients who do not want to participate in the study voluntarily * severe systemic disease (kidney, liver, pulmonary, endocrine) * substance abuse history * history of chronic pain * psychiatric problems and communication difficulties * patients who need revision due to hemostasis in the postoperative period * patients with severe hemodynamic instability due to infection, heavy bleeding, etc.

Keywords: erector spinae plane block combined serratus anterior plane block sternotomy
clinical investigation to assess the efficacy of manual toothbrushes in the reduction of plaque and gingivitis.

Conditions: Plaque, Dental; Gingivitis

Summary: qualified subjects will be enrolled and randomized to one of the two study groups based on their initial plaque and gingivitis scores. subjects will be instructed to use the products according to the instructions provided. subjects will return to the dental office for evaluation after 1, 3, and 6, weeks of unsupervised product use at home. all subjects will be followed for adverse events throughout the study


Eligibility criteria:
inclusion criteria: * signed informed consent form. * male and female subjects aged 18-70 years, inclusive. * availability for the six-week duration of the clinical research study. * good general health based on the opinion of the study investigator * minimum of 20 permanent natural teeth (excluding third molars). * initial gingivitis index of at least 1.0 as determined by the use of the loe and silness gingival index. * initial mean plaque index of at least 0.6 as determined by navy plaque index. exclusion criteria: * presence of orthodontic appliances. * presence of partial removable dentures. * tumor(s) of the soft or hard tissues of the oral cavity. * moderate and/or advanced periodontal disease, rampant caries, or any condition that the dental examiner considers exclusionary from the study. * five or more carious lesions requiring immediate restorative treatment. * antibiotic use any time during the one-month period prior to entry into the study. * participation in any other clinical study or test panel within the one month prior to entry into the study. * dental prophylaxis during the past two weeks prior to baseline examinations. * history of allergies to oral care/personal care consumer products or their ingredients. * on any prescription medicines that might interfere with the study outcome. * an existing medical condition that prohibits eating and/or drinking for periods up to 4 hours. * history of alcohol and/or drug abuse. * self-reported pregnancy and/or lactating subjects.
evaluating unilateral deep brain stimulation in patients with obsessive compulsive disorder

Conditions: Obsessive-Compulsive Disorder

Summary: the investigators previously showed that deep brain stimulation (dbs) in the bed nucleus of the stria terminalis (bnst) reduces symptoms in patients with severe obsessive-compulsive disorder (ocd). although most patients now receive bilateral stimulation, multiple studies suggest that stimulation of the left bnst might be equally effective. in this study, the investigators will evaluate the effect of unilateral stimulation in ocd patients who currently receive bilateral bnst stimulation to treat their symptoms. we hypothesize that unilateral stimulation of the left bnst will reduce anxious and depressive symptoms, compared to no stimulation. the study entails a double-blinded, randomized cross-over design during which every patient undergoes four stimulation conditions: stimulation of the left, right or bilateral bnst, or no stimulation. during every condition, which takes about fifteen minutes, the patient is exposed to an individually determined stimulus that normally elicits ocd-related symptoms. the patients are then asked to fill out a short questionnaire to evaluate the severity of their symptoms during the four conditions. at the end of the cross-over phase, the stimulation parameters of each patient are restored.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of obsessive-compulsive disorder * implanted with dbs system in the bilateral bst (or max. 4mm removed from the bst outline) * at least three months of chronic bst stimulation * compulsive behavior can be provoked within a clinical setting exclusion criteria: * personality changes evoked by chronic dbs * cognitive impairment

Keywords: (unilateral) deep brain stimulation anxiety mood
safety and pk-pd study of oral l-cit in preterm infants with bpd±ph and nec

Conditions: BPD - Bronchopulmonary Dysplasia; Pulmonary Hypertension; NEC

Summary: the purpose of this study is to evaluate the safety and explore the pk/pd of l-cit supplementation in preterm infants to prevent the development of inflammatory pathways initiated by low levels of plasma cit, specifically in preterm infants with post surgical nec and bpd±ph.

preterm infants are born with underdeveloped organs and immune systems, placing them at great risk for morbidity. they are more susceptible to inflammatory injury, particularly from conditions of prematurity mediated by inflammatory pathways such as bronchopulmonary dysplasia (bpd) and necrotizing enterocolitis (nec). l-cit, an amino acid, is the first intermediate in the urea cycle as well as a precursor to arginine and nitric oxide (no), which promotes blood flow. it is made in the intestine and has been shown to exert vasoprotective and anti-inflammatory effects. bpd-ph and nec are two specific inflammatory diseases of prematurity involving cit, arginine or no deficiencies. evaluation of the safety and pk/pd of l-cit supplementation for diseases involving cit, arginine or no deficiencies in preterm infants is important. therefore, in this trial the investigator would like to evaluate the safety and pharmacokinetics/pharmacodynamics (pd) of l-cit supplementation in preterm infants post surgical nec and bpd-ph.

Eligibility criteria:
arm 1: bpd±ph: inclusion criteria: * born ≤ 30 weeks at birth * post-menstrual age (pma) ≥ 34 weeks * echocardiographic evidence of ph for infants with bpd+ph * on invasive or non-invasive ventilation with rss \>2.0 for \>12hours/day for at least 48 hours * informed written consent (parents/substitute decision maker) exclusion criteria: * congenital heart disease \[exceptions: small atrial septal defect (asd), small ventricular septal defect (vsd), small patent ductus arteriosus (pda)\] * infants with pulmonary vein stenosis * concurrent sepsis with hemodynamic instability * infants considered likely to die within next 7 days * any other condition that, in the opinion of the investigator, may adversely affect the infant's ability to complete the study or its measures or pose significant risk to the infant. arm 2: surgical nec inclusion criteria * born ≤ 30 weeks at birth * recovering from stage iiib nec as per modified bell's staging (pneumoperitoneum requiring surgery) * tolerating 30 ml/kg/day of enteral feeds * on invasive or non-invasive ventilation (nippv/ncpap) with rss \>2.0 for \> 12hours/day for at least 48 hours, 10-14 days post surgery * informed written consent (parents/substitute decision maker) * considered medically stable by clinical team exclusion criteria: * congenital heart disease (except small asd, small vsd and non hspda) * pulmonary vein stenosis * concurrent sepsis with hemodynamic instability * likely to die within next 7 days * other condition significantly affecting pulmonary function independent of prematurity or nec

Keywords: bpd±ph surgical nec l-citrulline pharmacokinetic profile pharmacodynamic profile preterm neonates
surgery during covid-19: the role of asymptomatic patients, a survey

Conditions: Surgery; COVID; Asymptomatic Patient; Covid-19; Preventive Measures

Summary: a brief questionnaire to get a clearer picture of the situation regarding surgical patients with special emphasis on asymptomatic covid-19 patients.

with new evidence on the role of asymptomatic patients in spreading the disease during the covid-19 pandemic, symptom driven guidelines for testing, hospital allocation and personal protective equipment (ppe) use do not seem appropriate to limit in-hospital transmission. at time when lockdowns are in place in most countries, hospitals can become the new source of infection. guidelines are very variable depending on local policies and availability of medical supplies, resulting in most hospitals taking different preventive measures.

Eligibility criteria:
inclusion criteria: general surgeon exclusion criteria: other speciality
multimodal long covid19

Conditions: Long COVID-19 Syndrome

Summary: due to the covid-19 pandemic, the world has seen the need to identify groups of patients who experience various effects in the medium and long term after recovering from the initial illness. these medium- and long-term effects are collectively known as the post-covid-19 condition, long-covid, or prolonged covid. current evidence indicates, with conservative estimates, that between 10% and 20% of the population could be affected. its nature is varied and ranges from physical conditions such as chronic fatigue, dyspnea and muscle weakness, to neurocognitive (compromised memory, decreased concentration) and psychological (anxiety, depression, anguish, stress). early recognition and treatment of this symptom burden is essential for physical recovery and mental health. due to its multivariate nature, it has been suggested that optimal recovery of patients' quality of life would only be achieved to the extent that their main symptoms are addressed from an interdisciplinary perspective.


Eligibility criteria:
inclusion criteria: inclusion criteria will be: adults between 40 and 80 years of age. individuals will be included if they have had a positive polymerase chain reaction (pcr) test diagnosis of sars-cov-2 virus, presence of dyspnea and/or fatigue greater than 3 months after covid-19 diagnosis, at least 1 point higher on the modified medical research council scale (mmrc) compared to the period before infection. all participants must have no contraindications to perform the exercise and training tests and must be able to read, understand and sign the information and consent form. exclusion criteria: individuals with one of the exclusion criteria will not be eligible for our research project these are: pulmonary embolism; absolute and relative contraindication to cardiopulmonary stress testing or physical training; severe exercise intolerance, significant cardiac arrhythmias or ischemia during low intensity exercise, severe pulmonary hypertension; severe pulmonary disease (e.g.: chronic obstructive pulmonary disease, severe covid-19 related symptoms, severe asthma); recent cardiovascular event (cardiac decompensation, angioplasty or cardiac surgery less than 4 weeks old, valvular heart disease requiring surgical correction, pericarditis, ventricular rhythm disturbances and unstable despite treatment); renal failure requiring dialysis; heart failure (nyha iii or iv).

Keywords: multimodal covid19
use of eye exercises to improve vision

Conditions: Eye Strain

Summary: children in the united states watch an average of twenty-eight hours of television and play around thirteen hours of video games per week. the objective of this experiment was to see if a specific eye exercises could strengthen the eye muscles and improve the peripheral vision range of children and adults.

children in the united states watch an average of twenty-eight hours of television and play around thirteen hours of video games per week. when their eyes are focused, people tend to blink their eyes less, exacerbating the problem of eye fatigue or stress. the objective of this study is to see if a novel exercise technique can increase eye muscle strength and widen peripheral vision. experiments were conducted by asking the test subjects to follow, with their eyes, a set of blinking led lights on 3 vision exercise devices. these led lights were laid in circular or diagonal configurations, and programmed using a microcontroller to blink or 'move' in certain directions and at certain speeds. an endurance score, measured as total time that the test subject completed while following the blinking led lights before his/her eyes became tired, was recorded. nineteen test subjects aged 12-81 were asked to exercise their eyes four times over 2 weeks using the devices for as long as they could until they experienced mild eye fatigue. endurance scores, peripheral vision, and peripheral reading ranges were assessed before and after the training sessions.

Eligibility criteria:
inclusion criteria: * able to read english exclusion criteria: * cannot be colorblind
a study to assess the safety and efficacy of cat-2054 in combination with atorvastatin in patients with hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the purpose of this placebo-controlled, double-blind study is to assess the effect of several doses of cat-2054 on ldl-c in hypercholesterolemic patients on a stable dose of high-intensity statin, and to evaluate the safety and tolerability of different doses of cat-2054 for 4 weeks.


Eligibility criteria:
inclusion criteria: * between 18 and 74 years at screening * hypercholesterolemia (ldl-c ≥ 70 mg/dl and \< 190 mg/dl) plus a stable dose of statin for at least 4 weeks prior to screening * satisfies one of the following: 1. female patients of childbearing potential must have used appropriate and highly effective contraception (a regimen which results in a failure rate of \<1% per year) with their partners for 4 weeks prior to screening, and remain compliant during the treatment phase and until 4 weeks after the last dose of investigational product 2. male patients must use an acceptable and highly effective contraceptive method during the treatment phase and until 4 weeks after the last dose of investigational product * body mass index (bmi) ≤45 kg/m2 exclusion criteria: * history of any major cardiovascular event (stroke, tia, mi, ptci, cabg, hospitalization due to heart failure) within 6 months of screening * type i diabetes mellitus or use of insulin * active peptic ulcer disease or a history of muscle disease or myopathy
the effect of cilostazol on rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: the goal of this study is to evaluate the effect of cilostazol on rheumatoid arthritis patients. it aims to answer the questions of : 1. will cilostazol improve the disease severity and quality of life in rheumatoid arthritis patients? 2. will cilostazol decrease the oxidative stress, inflammation and endothelial dysfunction in rheumatoid arthritis patients? participants will be randomized into two arms either treatment or control the treatment group will be asked to take cilostazol 100 mg twice daily in addition to the usual dmard (methotrexate , sulfasalazine , hydroxychloroquine or leflunomide), while the control group will be taking the usual dmards only. patients in both arms will be followed-up every 2 weeks through out the 6-month duration of the study.

rheumatoid arthritis (ra) is an autoimmune disease affecting joints. it usually affects females more. the available treatment aims to slow down disease progression and control the disease symptoms. treatment is classified into either the conventional dmards (methotrexate , sulfasalazine , hydroxychloroquine or leflunomide) or biological dmards such as an anti-tnf alpha ( certolizumab, infliximab , etanercept or golimumab) or non-tnf biologics (rituximab, abatacept or tocilizumab). both classes have their drawbacks. the conventional dmards is not effective for many patients and the biological dmards have a high cost making their use limited to patients with medical insurance or patients who can afford it, thus making it necessary to find new medications which can improve the outcomes in patients with ra. cilostazol is an antiplatelet agent used mainly for intermittent claudication. recently many preclinical trials have shown efficacy of cilostazol in ra via it's anti-inflammatory action. it also decreases the oxidative stress which is high in ٌra patients. patients will be randomized into two arms , one which is treatment and the other is control the treatment group will be asked to take cilostazol 100 mg twice daily in addition to the usual dmard (methotrexate , sulfasalazine , hydroxychloroquine or leflunomide), while the control group will be taking the usual dmards only. patients in both arms will be followed-up every 2 weeks through out the 6-month duration of the study.

Eligibility criteria:
inclusion criteria: 1. adult patients. (\>18 years old). 2. moderate to high disease activity (das28-crp\>3.2). 3. patients receiving stable cdmard regimen for at least 3 months before inclusion in the study. exclusion criteria: 1. hypersensitivity to cilostazol. 2. heart failure. 3. pregnant and lactating women. 4. patients with liver impairment (alt or ast \> 3\* uln). 5. patients with renal impairment (crcl\<60 ml/min). 6. patients receiving any other antiplatelet or anticoagulant

Keywords: rheumatoid arthritis cilostazol
an evaluation of near-infrared spectroscopy for intracranial hematoma detection of head trauma patients in the emergency department.

Conditions: Within 12 Hrs of Head Injury

Summary: the purpose of this study is to evaluate near-infrared spectroscopy for intracranial hematoma detection of head trauma patients


Eligibility criteria:
inclusion criteria: the patients within 12 hours after head injury, visiting the emergency department of the national taiwan university hospital, and receiving computed tomography of head were enrolled. exclusion criteria: 1. the patients over 12 hours after head injury, visiting the emergency department of the ntuh, and receiving computed tomography of head were excluded. 2. patients with massive scalp laceration or hematoma were excluded. -

Keywords: head injury infrascanner intracranial hemorrhage